Recombinant Rat IL-1RA protein (rFc Tag)

Species

Rat

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3206

---

Validation Data Gallery

• 

  Purity of Recombinant Rat IL-1RA was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Rat IL-1RA protein His27-Gln178 (Accession# P25086) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 60582
• Accession: P25086
• PredictedSize: 44.6 kDa
• SDS-PAGE: 45-53 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Interleukin-1 receptor antagonist (IL-1RA) is a critical member of the IL-1 family of cytokines, which plays a significant role in modulating inflammatory responses. IL-1RA exists in two main forms: a secreted form (sIL-1Ra) and an intracellular form (icIL-1Ra). The secreted form is produced by various cells including monocytes, macrophages, neutrophils, and other cells, while the intracellular form is found in keratinocytes and other epithelial cells, as well as in monocytes and fibroblasts. IL-1RA acts as an anti-inflammatory agent by maintaining the balance between pro-inflammatory IL-1α/β and its own anti-inflammatory effects.

References:

1.Arend WP. (2002) Cytokine Growth Factor Rev. 13(4-5):323-340.
2.Spulber S, et al. (2009) Brain Behav Immun. 23(5):573-579. 
3.Gabay C, et al. (2010) Nat Rev Rheumatol. 6(4):232-241. 
4.Akash MS, et al. (2013) Pharm Res. 30(11):2951-2966.